DeCure for Nasopharyngeal type undifferentiated carcinoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for nasopharyngeal type undifferentiated carcinoma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNasopharyngeal type undifferentiated carcinoma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for nasopharyngeal type undifferentiated carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
A 2010 retrospective review of 2113 patients with nasopharyngeal malignancies registered over 25 years found only seven cases (0.33%) of rare nasopharyngeal malignancies, including adenocarcinoma, mucoepidermoid carcinoma, small cell carcinoma, lymphoma, and rhabdomyosarcoma. Two patients were initially misdiagnosed with undifferentiated carcinoma. Overall survival and progression-free survival for these rare malignancies were significantly worse than for conventional nasopharyngeal carcinoma (42.9% versus 74.8%, P=0.027; 42.9% versus 71.7%, P=0.016).
For conventional nasopharyngeal carcinoma, including the undifferentiated type, Epstein-Barr virus is almost constantly implicated in carcinogenesis, and the tumour retains p53 functionality and clonal characteristics up to late stages, which may account for high chemo- and radiosensitivity. A 2004 review notes that cisplatin-based induction chemotherapy has shown disease-free survival benefit, and concomitant chemoradiotherapy improves locoregional control. Long-term survivors have been reported even among patients with bone metastasis. However, late radiation-induced toxicities, especially xerostomia, remain a problem, and new agents such as taxanes and epidermal growth factor receptor inhibitors are of interest for circumventing resistance to alkylating agents.
A 2020 review describes treatment de-escalation strategies aimed at reducing irreversible toxic effects while maintaining disease control. Approaches include sparing chemotherapy in selected stage II patients, altering cisplatin scheduling or dosing, and decreasing radiotherapy dose or volume. These strategies are often guided by Epstein-Barr virus DNA levels, a robust biomarker for screening and monitoring, and by imaging modalities such as FDG-PET and dynamic contrast-enhanced MRI. Outcomes have remained excellent in most de-escalation studies, but patient selection is critical, and long-term outcomes and late complications are still unknown.
For recurrent disease, a 2014 case report states that survival expectancy with chemotherapy alone as salvage treatment is approximately 6 months. In that case, a durable complete response was achieved with a combination of chemotherapy, radiotherapy, and surgery in a multidisciplinary setting. What is still missing are prospective, multi-institutional studies to determine how to individualise and de-escalate treatment safely, and better evidence for managing recurrent disease beyond single case reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA Oncology · 2020 · 31 citations
Treatment Deescalation Strategies for Nasopharyngeal Cancer
AbstractIMPORTANCE: Since the advent of modern radiotherapy techniques and incorporation of systemic chemotherapy for nasopharyngeal cancer, locoregional control has been excellent. However, the rate of treatment-related complications, many of which are irreversible, remains high. New approaches are being explored to determine whether the toxic effects of treatment can be relieved while maintaining disease control. This review presents the current state of deescalation strategies for nasopharyngeal cancer. OBSERVATIONS: A review of the literature shows that deescalation approaches can be generally categorized into deescalating systemic therapy vs deescalating radiotherapy. This review discusses studies that have explored sparing chemotherapy in selected patients with stage II cancer as well as altering the chemotherapy scheduling, dosing, and agent from the current standard of care, cisplatin. Deescalating radiotherapy has involved decreasing the dose and the treatment volume. In many cases, these approaches are being guided by measuring Epstein-Barr virus DNA levels, which is a robust biomarker for screening, treatment monitoring, and surveillance. Ongoing work with various imaging modalities, such as fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced or diffusion-weighted magnetic resonance imaging sequences, have shown promise as another biomarker to safely guide practitioners toward deescalation. CONCLUSIONS AND RELEVANCE: Various strategies to deescalate treatment in nasopharyngeal cancer have been explored, and outcomes have remained excellent in most approaches. Patient selection remains key, and long-term outcomes and late complications are still to be determined. Continued investigation with prospective, multi-institutional studies are needed to better elucidate how treatment for nasopharyngeal carcinoma can best be individualized and deescalated.
AbstractPURPOSE OF REVIEW: Given the high rate of mortality still associated with advanced stages of nasopharyngeal carcinoma, this review focuses on some specific aspects of this potentially curable disease that could translate into improved therapeutic approaches. RECENT FINDINGS: Epstein-Barr viral-induced carcinogenesis is almost constantly reported in the undifferentiated type of nasopharyngeal carcinoma. Nasopharyngeal carcinoma retains clonal characteristics and p53 functionality up to late stages that may account for its high level of chemo- and radiotherapy sensitivity, with several cases of long-term survivors reported among patients with bone metastasis. Recent imaging and biologic techniques will help to identify patients at risk of distant failures (detection of plasma Epstein-Barr virus DNA) or those harboring posttherapeutic residual diseases (positron emission tomographic scan). Cisplatin-based induction chemotherapy has shown disease-free survival benefit, whereas concomitant chemoradiotherapy is associated with an improved local-regional control. Late radiation-induced toxicities (especially xerostomia) will hopefully be reduced using intensity-modulated radiation therapy. New therapeutic agents such as taxanes, or targeted therapies (epidermal growth factor receptor inhibitors) are of major interest in the challenge of circumventing resistance to alkylating agents. SUMMARY: Better knowledge of nasopharyngeal carcinoma pathogenesis and biology, management of patients in highly specialized oncologic units, and careful selection of cytotoxic agents along with multimodality integrated therapeutic programs will likely yield to improved survival, particularly for patients with locally advanced nasopharyngeal carcinoma.
World Journal of Clinical Cases · 2014 · 8 citations · open access
Optimal management of a patient with recurrent nasopharyngeal carcinoma
AbstractNasopharyngeal carcinoma is rare in western countries, accounting for less than 1% of all malignancies. Despite prognosis is satisfactory for newly diagnosed, non-metastatic disease, management of recurrent disease is challenging, with a survival expectancy of approximately 6 mo with the use of chemotherapy as the sole salvage treatment. We report a case of recurrent nasopharyngeal carcinoma treated with a combination of chemotherapy, radiotherapy and surgery in the context of a multidisciplinary approach. A durable complete response was achieved.
Rare Malignancies of the Nasopharynx-25-Year Clinical Experience of a Medical Center
AbstractPurpose: Nasopharyngeal malignancies, other than squamous cell carcinoma and undifferentiated carcinoma, are rare. We investigated the clinical manifestations and treatment outcomes of patients with rare nasopharyngeal malignancies over a 25-year period. Materials and Methods: From January 1983 to December 2008, a total of 2113 patients with nasopharyngeal malignancies were registered in our radiotherapy database. Only seven eligible patients with rare malignancies of the nasopharynx were found. We retrospectively reviewed hospital charts, radiotherapy records, and imaging studies. The clinical courses and final outcomes were analyzed. Survival was compared with another group of patients with stage II-IVb conventional nasopharyngeal carcinoma (NPC). treated by concomitant chemoradiotherapy. Results: The incidence of rare nasopharyngeal malignancies was only 0.33%. The pathologic diagnoses were three rare carcinomas (adenocarcinoma, mucoepidermoid carcinoma, and small cell carcinoma), three lymphomas and one rhabdomyosarcoma. The initial manifestations were similar to conventional NPC. Two patients were misdiagnosed with conventional NPC (undifferentiated carcinoma), but this was revised to rhabdomyosarcoma and malignant lymphoma when distant sites relapsed. The overall survival and progression-free survival of the study group were significantly worse than conventional NPC (42.9% vs. 74.8%, P=0.027; 42.9% vs. 71.7%, P=0.016, respectively). Conclusion: Rare malignancies arising from the nasopharynx consist of several different pathologies. The accurate diagnosis of rare malignancies of the nasopharynx depends on high index of suspicious of pathologist. The treatment outcome is worse than conventional NPC.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
